The compositions and methods described herein relate to the treatment of cancer, e.g. by reducing the regression of cancer cells from regressing into cancer stem cell-like phenotypes and/or reducing the development of drug-resistant cancer cells. In some embodiments, the compositions and methods relate to inhibitors of PI3K pathway kinases and Src family kinases.
